• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Twitter and life sciences: How to get it right

Twitter and life sciences: How to get it right

September 13, 2011 By MassDevice Contributors Network

(Photo: Chinen Keiya/Flickr)

By Maude Tessier

Like many, I have a Facebook page where I share funny travel stories and cute pictures of my cat with friends and family.

But for a long time I didn’t understand how such a platform, and others like Twitter, could affect how business is conducted in the life science industry, and how it fit in my own professional life as a hospital technology licensing manager.

I didn’t get it until a tweet from my colleague and fellow blogger Keeley Wray (@Market_Spy) established a direct contact with a regenerative medicine company potentially interested in a cell-based technology in my portfolio. I was surprised: so Twitter isn’t just for celebrities pushing their albums, movies and perfumes to millions of fans? Consequently, six months ago, I enthusiastically joined the Twitterverse (@maude_tessier) and haven’t looked back.

Vector

I’m not the only one recognizing the power of social media in the work that pharma, biotech and academic medical institutions do. Last week at theBioPharm America conference, a 90-minute interactive roundtable discussion emphasized the use of social media to help achieve business objectives. Panelists were Bruce Booth, partner at Atlas Ventures (@LifeSciVC); Cynthia Clayton, senior director of investor relations and corporate communications at Alnylam Pharmaceuticals (@Alnylam); Adam Feuerstein, senior columnist for TheStreet (@adamfeuerstein); John Carroll, editor of FierceBiotech (@JohnCFierce); Michael Gilman, CEO of Stromedix (@Michael_Gilman), Carlos Velez, managing partner at LacertaBio (@LacertaBio); and Daphne Zohar, founding and managing partner, PureTech Ventures (@daphnezohar). Watch the full session, moderated by Steve Dickman, founder/CEO of CBT Advisors (@cbtadvisors), on PartneringNews.

Bruce Booth noted that, compared to other industries like IT, life-science voices are currently underrepresented on Twitter. Moreover, out of all current Twitter members, 70-80 percent have put out fewer than 10 tweets. But there’s plenty of room to grow. I share Daphne Zohar’s view that it’s important that an increasing number of executives “be part of the conversation.”

If you’re life sciences or healthcare, why should you spend your valuable time on Twitter? The savvy panelists made a compelling case for Twitter as:

  • An ideal source for real time data/news to inform business strategies
  • A helpful forum to poll the community on a subject
  • A platform to comment on the state of the life science industry
  • A way to better understand how people think
  • A tool to make new connections with companies and patient groups
  • A medium to build credibility for you and your organization

Vector blog readers and members of the life science community, the Twitterverse needs you. For those just starting, the panel offered a few pointers:

  • Create separate work and personal accounts, or focus one feed on professional content at least 90 percent of the time
  • Review your organization’s social media guidelines and policies
  • Put a disclaimer on your profile if you are not an officially designated representative of your organization (Keeley’s and mine say “Tweets own opinions”)
  • Begin by “following” coworkers, colleagues and companies you are interested in, and look at their list of followers
  • Retweet posts that you find stimulating
  • Remember that tweets are public and forever. Think before posting (there is no “are you sure?” button!)
  • Create lists using hashtags (keywords preceded by #) to keep up to date on what matters most to you. For example, the feed for this conference was #BPA11.

If you’re concerned that social media are taking over our lives and that face-to-face contact is being minimized, I would like to alleviate your fears. I agree with Michael Gilman’s view that Twitter is “a tool to build relationships, not to avoid personal interactions.” I met folks in person at Biopharm America that I’d been following on Twitter for months, and already felt a connection with them. Other attendees I did not know — like Luke Timmerman, National Biotech Editor of Xconomy — noticed the live tweets I was posting during the conference (another advantage of Twitter – free virtual attendance at conferences!) and started following me. Some introduced themselves and exchanged business cards with me. I’m now following them on Twitter, too.

As Keeley pointed out in her recent BioPharm coverage, life science stakeholders are a family, and we need to work together to tackle unmet medical needs. Joining the Twitter community is a great way to promote useful interactions, begin to address the challenges and capitalize on the opportunities in our industry. I look forward to welcoming you to the Twitterverse!

Maude Tessier, PhD, is a licensing manager in the Children’s Hospital Boston’s Office of Technology and Innovation Development. She is responsible for managing and licensing technologies from the Vascular Biology Program, Nephrology, Urology and Respiratory Diseases.

Filed Under: Health Information Technology, News Well

More recent news

  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment
  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Medtronic issues safety notice for Hugo surgical robot console in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy